{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-8VYWL4U8/dee385f7-66b9-4711-b258-bac929e29cb2/PDF","dcterms:extent":"185 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-8VYWL4U8/66b261ba-261d-4c7d-8f69-3d28b986d7f7/TEXT","dcterms:extent":"21 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-8VYWL4U8","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2014","dc:creator":["Ilaš, Janez","Obreza, Aleš"],"dc:format":[{"@xml:lang":"sl","#text":"številka:5"},{"@xml:lang":"sl","#text":"letnik:65"},{"@xml:lang":"sl","#text":"str. 337-343"}],"dc:identifier":["ISSN:0014-8229","COBISSID:3801201","URN:URN:NBN:SI:doc-8VYWL4U8"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"en","#text":"alpha-adrenoreceptor antagonists"},{"@xml:lang":"sl","#text":"antagonisti adrenergičnih receptorjev alfa"},{"@xml:lang":"en","#text":"benign hyperplasia of prostate"},{"@xml:lang":"sl","#text":"benigna hiperplazija prostate"},{"@xml:lang":"sl","#text":"lajšanje težav"},{"@xml:lang":"en","#text":"testosterone 5-alpha reductase inhibitors"},{"@xml:lang":"sl","#text":"zaviralci testosteron-5-alfa reduktaze"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Zdravila za zdravljenje benigne hiperplazije prostate| Drugs for treating benign hyperplasia of prostate|"},"dc:description":[{"@xml:lang":"sl","#text":"The most important synthetic drugs used for treating benign hyperplasia of prostate are presented in the article. Active ingredients of two pharmacological groups are almost exclusively used, alpha-adrenoreceptor antagonists and testosterone-5-alpha reductase inhibitors. Briefly, some drugs, recently described in scientific and professional literature for the relief of symptoms are also mentioned"},{"@xml:lang":"sl","#text":"V prispevku je predstavljen pregled najpomembnejših sinteznih učinkovin, ki se uporabljajo za zdravljenje benigne hiperplazije prostate. Skoraj izključno se uporabljajo zdravilne učinkovine iz dveh skupin, antagonistov adrenergičnih receptorjev alfa in zaviralcev testosteron-5-alfa reduktaze. Na kratko bodo omenjene tudi nekatere druge učinkovine, ki so bile za namen lajšanja težav v zadnjem času opisane v strokovni in znanstveni literaturi"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-8VYWL4U8","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-8VYWL4U8"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-8VYWL4U8/dee385f7-66b9-4711-b258-bac929e29cb2/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-8VYWL4U8/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-8VYWL4U8"}}}}